Targeting novel peripheral mediators for the treatment of chronic pain.

Research efforts over the past two decades have helped us better understand the biological mechanisms that lead to chronic pain. Despite this, there has been limited progress in developing novel analgesics to treat sufferers of persistent pain conditions, who may account for as many as one-fifth of the population. A re-evaluation of the strategies used to discover pain-relieving drugs is needed to meet this widespread clinical need. Here, we discuss the merits of pursuing peripherally acting pain mediators. We review the significant clinical evidence that neuronal activity from the periphery is a major contributor to painful symptom production and that peripheral mediators play a substantial role in this aberrant nociceptor activity. We discuss the clinical benefits of blocking individual known mediators and describe our own approach to identify novel mediators.

[1]  R. LaMotte,et al.  Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. , 1991, Journal of neurophysiology.

[2]  Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. , 2006, Joint, bone, spine : revue du rhumatisme.

[3]  M. Devor,et al.  Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[4]  T. Schnitzer,et al.  Tanezumab for the treatment of pain from osteoarthritis of the knee. , 2010, The New England journal of medicine.

[5]  J. Wood,et al.  Voltage-gated sodium channels. , 2001, Current opinion in pharmacology.

[6]  M. Sanders,et al.  Effectiveness of acute postoperative pain management. , 2003, British journal of anaesthesia.

[7]  J. Bland,et al.  Effectiveness of acute postoperative pain management: I. Evidence from published data. , 2002, British journal of anaesthesia.

[8]  A. Fioravanti,et al.  Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study , 2009, Rheumatology International.

[9]  F. Cunha,et al.  Caspase-1 is involved in the genesis of inflammatory hypernociception by contributing to peripheral IL-1β maturation , 2010, Molecular pain.

[10]  S. Ferreira.  Peripheral analgesia: mechanism of the analgesic action of aspirin-like drugs and opiate-antagonists. , 1980, British journal of clinical pharmacology.

[11]  Patrick D. Wall,et al.  Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction , 1992, Pain.

[12]  W. Kingery,et al.  A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes , 1997, Pain.

[13]  M. Devor.  Sodium channels and mechanisms of neuropathic pain. , 2006, The journal of pain : official journal of the American Pain Society.

[14]  Sheena Derry,et al.  Systematic review of topical capsaicin for the treatment of chronic pain , 2004, BMJ : British Medical Journal.

[15]  Stephen B. McMahon,et al.  Inflammatory mediators and modulators of pain , 2005 .

[16]  S. McMahon,et al.  Ultraviolet-B-induced mechanical hyperalgesia: A role for peripheral sensitisation , 2010, PAIN.

[17]  R. Potts,et al.  Local Enhanced Topical Delivery (LETD) of Drugs: Does It Truly Exist? , 1992, Pharmaceutical Research.

[18]  M. Cutolo,et al.  Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects , 2006, Annals of the rheumatic diseases.

[19]  C. Bombardier,et al.  Health-related quality of life after knee replacement. , 1998, The Journal of bone and joint surgery. American volume.

[20]  G. Habib,et al.  Local effects of intra-articular corticosteroids , 2010, Clinical Rheumatology.

[21]  C. Birbara,et al.  Efficacy and safety of tanezumab in the treatment of chronic low back pain , 2011, PAIN®.

[22]  D. Howes.  Sensation , 2011, The Drama of Celebrity.

[23]  S. Bevan,et al.  PGE2 modulates the tetrodotoxin‐resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP‐protein kinase A cascade. , 1996, The Journal of physiology.

[24]  R. Baron,et al.  Efficacy and Safety of 5% Lidocaine (Lignocaine) Medicated Plaster in Comparison with Pregabalin in Patients with Postherpetic Neuralgia and Diabetic Polyneuropathy , 2009, Clinical drug investigation.

[25]  S. McMahon,et al.  The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule , 1995, Nature Medicine.

[26]  R. Dantzer,et al.  Low Nociceptor GRK2 Prolongs Prostaglandin E2 Hyperalgesia via Biased cAMP Signaling to Epac/Rap1, Protein Kinase Cε, and MEK/ERK , 2010, The Journal of Neuroscience.

[27]  G. Wall,et al.  Oral versus topical NSAIDs in rheumatic diseases: a comparison. , 2000, Drugs.

[28]  J. Ochoa,et al.  Early and late effects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilatation in humans , 1991, Pain.

[29]  Gary J. Bennett,et al.  Painful neuropathy: altered central processing maintained dynamically by peripheral input , 1992, Pain.

[30]  Robert S. Dittus,et al.  Health-Related Quality of Life after Knee Replacement: Results of the Knee Replacement Patient Outcomes Research Team Study* , 1998 .

[31]  F. Cunha,et al.  Cytokine‐mediated inflammatory hyperalgesia limited by interleukin‐1 receptor antagonist , 2000, British journal of pharmacology.

[32]  C. Woolf,et al.  Prostaglandin E2 Receptor EP4 Contributes to Inflammatory Pain Hypersensitivity , 2006, Journal of Pharmacology and Experimental Therapeutics.

[33]  A. Te.  A Study to Investigate Tanezumab in Patients with Interstitial Cystitis/Painful Bladder Syndrome , 2011, Current urology reports.

[34]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[35]  M. Nolano,et al.  Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation , 1999, Pain.

[36]  M. Tominaga,et al.  Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. , 2002, Journal of neurophysiology.

[37]  D. Bouhassira,et al.  Intravenous lidocaine in central pain , 2000, Neurology.

[38]  M. Rowbotham,et al.  Topical lidocaine gel relieves postherpetic neuralgia , 1995, Annals of neurology.

[39]  R. Terkeltaub,et al.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study , 2009, Annals of the rheumatic diseases.

[40]  I. Iqbal,et al.  Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis , 2004, Expert opinion on biological therapy.

[41]  K. Chapman,et al.  The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights , 2011, Molecular and Cellular Endocrinology.

[42]  Q. Smith,et al.  Brain Uptake of Nonsteroidal Anti-Inflammatory Drugs: Ibuprofen, Flurbiprofen, and Indomethacin , 2006, Pharmaceutical Research.

[43]  P. L. McCormack.  Capsaicin Dermal Patch , 2010, Drugs.

[44]  T. Yaksh,et al.  Mechanism of action of nonsteroidal anti-inflammatory drugs. , 1998, Cancer investigation.

[45]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[46]  H. Kautiainen,et al.  Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice. , 2009, Clinical and experimental rheumatology.

[47]  Y. Hong,et al.  Behavioural effects of intraplantar injection of inflammatory mediators in the rat , 1994, Neuroscience.

[48]  J. Zakrzewska,et al.  Wall and Melzack's textbook of pain , 2006 .

[49]  M. Rowbotham,et al.  Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia , 1996, Pain.

[50]  Sophie Pezet,et al.  Neurotrophins: mediators and modulators of pain. , 2006, Annual review of neuroscience.

[51]  M. Koltzenburg,et al.  Dynamic and static components of mechanical hyperalgesia in human hairy skin , 1992, Pain.

[52]  J. Bogousslavsky,et al.  Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study , 2003, Pain.

[53]  Paul Dieppe,et al.  Persistent pain after joint replacement: Prevalence, sensory qualities, and postoperative determinants , 2011, PAIN®.

[54]  S. McMahon,et al.  Wall and Melzack's textbook of pain , 2006 .

[55]  B. Collett,et al.  Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment , 2006, European journal of pain.

[56]  Christine Orengo,et al.  CXCL5 Mediates UVB Irradiation–Induced Pain , 2011, Science Translational Medicine.